Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

NCT02360215 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT02360215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02360215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
August 26, 2019
Enrollment
518 (actual)
Sites
220

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, metastatic malignant neoplasm in the brain, solid neoplasm